1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Mats Heyman: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy - Leukemia, Acute Lymphoblastic | Phase 3 | Recruiting | Mats Heyman | 6430 | 2020-07-13 | 2026-08-12 |
Leukemia (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Imatinib Mesylate (1) · blinatumomab (1)
Belgium (1) · Denmark (1) · Estonia (1) · Finland (1) · France (1) · Germany (1) · Iceland (1) · Ireland (1) · Lithuania (1) · Netherlands (1) · Norway (1) · Portugal (1) · Spain (1) · Sweden (1) · United Kingdom (1)